India’s Cipla Lines Up Foreign Governments For Its Tamiflu Generic
This article was originally published in PharmAsia News
Executive SummaryCipla of India says it has reached an agreement to sell its generic version of Roche's Tamiflu (oseltamivir) to Mexico to treat the A/H1N1 flu virus. The World Health Organization has declared Cipla's Antiflu as effective as Roche's branded product. Cipla's head, Yusuf Hamled, said the company also is negotiating similar arrangements with several other countries in Africa, Latin America and the Middle East. Roche and Tamiflu's patent holder, Gilead, recently lost an Indian court case against the Cipla generic. (Click here for more
You may also be interested in...
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.